Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.13819Source: DataRank Database

Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials is a research paper published in JAMA Network Open (2023). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.38)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Joseph Abi Jaoude ORCID,Roshal R. Patel ORCID,Ramez Kouzy ORCID,Timothy A. Lin ORCID,Brian De ORCID

Live enrichment

PubMed:37195664 PMC:PMC10193180 OpenAlex:https://openalex.org/W4376872635

NCI NIH HHS

Grant: P30 CA016672

NHLBI NIH HHS

Grant: F31 HL156500

National Institutes of Health

Grant: 5F31HL156500-02

ESTABLISHING THE ROLE OF BONE MARROW STROMAL ANTIGEN 2 IN HEMATOPOIETIC STEM CELL NICHE INTERACTIONS AND ACTIVATION

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2805005/florez_2023_oi_230424_1683726851.60325.pdf

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2805005/florez_2023_oi_230424_1683726851.60325.pdf

journalhttps://doi.org/10.1001/jamanetworkopen.2023.13819

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37195664

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10193180

Fields of Study

Cancer survivorship and careBreast Cancer Treatment StudiesStatistical Methods in Clinical Trials03 medical and health sciences0302 clinical medicineHumansIncidenceRandomized Controlled Trials as TopicMedical OncologyBiasNeoplasms

MeSH Terms

HumansMedical OncologyNeoplasmsBiasIncidenceRandomized Controlled Trials as Topic

Keywords

MedicineClinical trialRandomized controlled trialClinical endpointInternal medicineIncidence (geometry)Surrogate endpointAdverse effectProtocol (science)Logistic regressionOncologyPathologyAlternative medicineMedical SciencesBioinformaticsIncidence610Medical OncologyBiomedical InformaticsBiasNeoplasmsMedical SpecialtiesMedicine and Health SciencesHumansOriginal InvestigationRandomized Controlled Trials as Topic

Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials

FAIR Checklist

Authors (16)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)